abbvie
Entity, reached from Hormuz.
- Evidence
- 98 documents · 30 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 30 Apr 2026, last seen 8 Oct 2026
- Measured
- 21% of mentions say something specific about it; the rest only name it
- As of
- 9 Oct 2026
Where this comes from
- Fierce Pharma · 2026-10-07 · AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy (opens the source in a new tab)
- PR Newswire · 2026-10-07 · AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC (opens the source in a new tab)
- AllSci News · 2026-10-06 · Genmab, AbbVie report 51% reduction in progression or death with frontline epcoritamab (opens the source in a new tab)
- Endpoints News · 2026-10-06 · AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-06 · AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial (opens the source in a new tab)
- Fierce Biotech · 2026-10-05 · Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere (opens the source in a new tab)
- AllSci News · 2026-10-02 · AbbVie’s zumilokibart clears Phase II with potential for quarterly or twice-yearly dosing (opens the source in a new tab)
- Endpoints News · 2026-10-01 · AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117 (opens the source in a new tab)
- 24/7 Wall St. · 2026-09-30 · BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength (opens the source in a new tab)
- The Clinical Trial Vanguard · 2026-09-30 · AbbVie’s Zumilokibart Meets Primary Endpoint in Phase 2 Atopic Dermatitis Study (opens the source in a new tab)
Links from here: not yet read.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with fda (33 documents)seen together
- co-mentioned with eli lilly (21 documents)seen together
- co-mentioned with merck (20 documents)seen together
- co-mentioned with amgen (19 documents)seen together
- co-mentioned with pfizer (19 documents)seen together
- co-mentioned with roche (18 documents)seen together
- co-mentioned with nasdaq (17 documents)seen together
- co-mentioned with novartis (16 documents)seen together
- co-mentioned with nyse (16 documents)seen together
- co-mentioned with astrazeneca (15 documents)seen together